Modus Therapeutics granted two European Patents
STOCKHOLM, SWEDEN – 21 February 2018: Modus Therapeutics AB, a company developing innovative treatments in high unmet medical need disease areas with a focus on sickle cell disease (SCD), announces that the European Patent Office has granted to the Company two European patents.
Modus has been granted a substance patent for its development compound sevuparin, as well as a medical use patent in SCD. Both these granted European patents have been validated in all 39 available European countries.
The two granted patents in Europe represent an important milestone for the company, and sevuparin is now patent protected in the major markets US, Canada, and EU, as well as in many other important countries.
Sevuparin is an innovative chemically modified heparin, having the ability to restore blood flow during microvascular obstructions by exerting its anti-adhesive effects via several key adhesion receptors. This proprietary compound has the potential to be beneficial in several clinical indications, where blood flow is restricted. One such indication is Sickle Cell Disease (SCD), which is a disease affecting millions of people around the globe and which is caused by a mutation in the hemoglobin gene. SCD patients’ red blood cells form a sickled shape and become sticky, attaching to vessels walls and other blood cells. This leads to a reduced blood flow and impaired transport of oxygen to vital organ.
SCD is an inherited blood disorder characterized by severe pain leading to organ damage, which affects between 90,000-100,000 individuals in the U.S. Progressive organ damage limits the life expectancy of patients with SCD and lifetime medical care costs can exceed $1M per patient with an estimated $1B spent annually in the U.S.